Prospective follow-up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome

Human Reproduction
Maryse BonduellePaul Devroey

Abstract

Is treatment with corifollitropin alfa, a new recombinant gonadotrophin with sustained follicle-stimulating activity, safe in terms of perinatal complications and birth defects in infants conceived following corifollitropin alfa treatment for contolled ovarian stimulation (COS)? In terms of neonatal outcome and risk of malformations, treatment with a single dose of corifollitropin alfa during COS is as safe as treatment with daily recombinant FSH (rFSH). This is the first pooled analysis of individual safety data in terms of neonatal outcome and major and minor congenital malformations collected following intervention trials of corifollitropin alfa. Pregnancy and follow-up studies were conducted prospectively and data were collected from all Phase II and III trials with corifollitropin alfa intervention, including two comparative randomized controlled trials (RCTs) in which patients received either a single dose of corifollitropin alfa or daily rFSH for the first 7 days of COS. Patients with ongoing pregnancies at 10 weeks after embryo transfer were followed up to labour and the health of the offspring was assessed up to 4-12 weeks after birth. Following corifollitropin alfa treatment prior to IVF or ICSI, the health of 677 pre...Continue Reading

References

Apr 1, 1987·The Journal of Pediatrics·K A LeppigL B Holmes
Dec 1, 1996·Human Reproduction·J L Simpson
Mar 3, 2001·Human Reproduction·A Ericson, B Källén
Mar 8, 2002·The New England Journal of Medicine·Michèle HansenSandra Webb
Aug 2, 2002·Human Reproduction·Peter J BoerrigterDorrie P J Passier-Timmermans
Aug 2, 2002·Human Reproduction·S AnthonyA L den Ouden
Nov 30, 2004·Human Reproduction·Michèle HansenJennifer J Kurinczuk
Feb 12, 2005·Journal of Assisted Reproduction and Genetics·Alfred A RimmK Paul Katayama
Jul 6, 2007·Acta Obstetricia Et Gynecologica Scandinavica·Karl-Gösta NygrenPetra Otterblad Olausson
Jul 31, 2007·Lancet·Alastair G Sutcliffe, Michael Ludwig
Nov 18, 2008·Human Reproduction·J ReefhuisUNKNOWN National Birth Defects Prevention Study
May 5, 2009·Fertility and Sterility·Jaime KnopmanNicole Noyes
Feb 13, 2010·Fertility and Sterility·Human M FatemiPaul Devroey
Mar 9, 2010·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Shi Wu WenMark C Walker
May 21, 2010·Reproductive Biomedicine Online·UNKNOWN Corifollitropin alfa Ensure Study Group
Dec 1, 2010·European Journal of Pharmacology·Pieter VerbostGijs F M Verheijden
Jun 15, 2011·Reproductive Biomedicine Online·William L LedgerBernadette M J L Mannaerts

❮ Previous
Next ❯

Citations

Jul 15, 2015·The Cochrane Database of Systematic Reviews·Annefloor W PouwerJan A M Kremer
Feb 13, 2019·Human Reproduction Update·Sine BerntsenAnja Pinborg
Jul 14, 2021·Journal of Assisted Reproduction and Genetics·Jon HavelockUNKNOWN ESTHER-1 and ESTHER-2 Trial Groups

❮ Previous
Next ❯

Related Concepts

Related Feeds

Absence Epilepsy

Absence epilepsy is a common seizure disorder in children which can produce chronic psychosocial sequelae. Discover the latest research on absence epilepsies here.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.